Heidelberg Pharma AG (XTER:HPHA) 3-Year Dividend Growth Rate : 0.00% (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG 3-Year Dividend Growth Rate?

Heidelberg Pharma AG's Dividends per Share for the three months ended in Feb. 2024 was €0.00.

The historical rank and industry rank for Heidelberg Pharma AG's 3-Year Dividend Growth Rate or its related term are showing as below:

XTER:HPHA's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Heidelberg Pharma AG's Dividend Payout Ratio for the three months ended in Feb. 2024 was 0.00. As of today, Heidelberg Pharma AG's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Heidelberg Pharma AG's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Heidelberg Pharma AG's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's 3-Year Dividend Growth Rate falls into.

Heidelberg Pharma AG 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Heidelberg Pharma AG (XTER:HPHA) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Heidelberg Pharma AG's Dividend Payout Ratio for the quarter that ended in Feb. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Feb. 2024 )	/	EPS without NRI (Q: Feb. 2024 )
	=	0	/	-0.1
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG 3-Year Dividend Growth Rate Related Terms>

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines